Abstract
Background
Recurrent primary biliary cirrhosis (PBC) is frequently observed in patients with
PBC after liver transplantation (LT). We performed a meta-analysis to evaluate the
risk factors for PBC recurrence.
Methods
We searched the EMBASE, PubMed and the Cochrane Library databases for studies published
before August 2020. Studies that identified the risk factors of PBC recurrence were
eligible for inclusion. We extracted the hazard ratio (HR) data with 95% confidence
intervals (CI) for the risk factors.
Results
Our meta-analysis included 6 studies, which comprised 3184 patients (88.5% females)
who underwent liver transplantation from 1982 to 2017, and of these patients, 935
(29.4%) developed PBC recurrence. The use of tacrolimus (HR = 2.62, 95% CI = 1.35,
5.09) and preventive ursodeoxycholic acid (UDCA) (HR = 0.40, 95% CI = 0.28, 0.57)
were significantly associated with the risk of PBC recurrence based on the pooled
analysis of the results obtained from the multivariate analysis.
Conclusions
The use of tacrolimus is associated with an increased risk of PBC recurrence. Preventive
UDCA after LT for PBC can help to prevent disease recurrence.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Digestive and Liver DiseaseAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Primary biliary cirrhosis.Lancet. 2015; 386: 1565-1575
- The limitations and hidden gems of the epidemiology of primary biliary cirrhosis.J Autoimmun. 2013; 46: 81-87
- Clinical updates in primary biliary cholangitis: trends, epidemiology, diagnostics, and new therapeutic approaches.J Clin Transl Hepatol. 2020; 8: 49-60
- Primary biliary cirrhosis.Semin Immunopathol. 2009; 31: 283-307
- Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence.J. Hepatol. 2003; 39: 142-148
- Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation.Liver Transpl. 2009; 15: S25-S34
- Cyclosporine A protects against primary biliary cirrhosis recurrence after liver transplantation.Am J Transpl. 2010; 10: 852-858
- Disease recurrence after living liver transplantation for primary biliary cirrhosis: a clinical and histological follow-up study.Liver Transpl. 2001; 7: 588-595
- Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center.Hepatology. 2001; 33: 22-27
- Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression.J Hepatol. 1996; 24: 253-257
- Factors associated with recurrence of primary biliary cholangitis after liver transplantation and effects on graft and patient survival.Gastroenterology. 2019; 156: 96-107
- Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: a Japanese multicenter retrospective study.Hepatol Commun. 2017; 1: 394-405
- Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence.J Hepatol. 2015; 63: 1449-1458
- GS-18-Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival.J Hepatol. 2019; 70: e84
- Long-term outcomes of living-donor liver transplantation for primary biliary cirrhosis: a Japanese multicenter study.Am J Transpl. 2016; 16: 1248-1257
- Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity.Liver Transpl. 2010; 16: 64-73
- Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation.Liver Transpl. 2004; 10: 488-491
Sterne J.A., Sutton A.J., Ioannidis J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011;343:d4002.
- Practical methods for incorporating summary time-to-event data into meta-analysis.Trials. 2007; 8: 16
- Measuring inconsistency in meta-analyses.BMJ. 2003; 327: 557-560
- Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis.J Hepatol. 2020; 73: 559-565
- Recurrent primary biliary cirrhosis after liver transplantation.Am J Transpl. 2010; 10: 720-726
- Clinical relevance of recurrence of primary biliary cirrhosis after liver transplantation.Eur J Gastroenterol Hepatol. 1999; 11: 639-642
- Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.Transpl Proc. 2005; 37: 1691-1692
- Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant.Liver Transpl. 2005; 11: 1252-1257
- Concentrations of cyclosporin A and FK506 that inhibit IL-2 induction in human T cells do not affect TGF-beta1 biosynthesis, whereas higher doses of cyclosporin A trigger apoptosis and release of preformed TGF-beta1.J Leukoc Biol. 2005; 77: 748-758
- Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin.Transplantation. 2008; 86: 1292-1300
- The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation.Transplantation. 2003; 76: 1583-1588
- Weaning of immunosuppression in liver transplant recipients.Transplantation. 1997; 63: 243-249
- European Association for the Study of the L. EASL Clinical Practice Guidelines: management of cholestatic liver diseases.J Hepatol. 2009; 51: 237-267
- A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis.Hepatology. 1995; 22: 759-766
- Ursodeoxycholic acid in the treatment of primary biliary cirrhosis.Gastroenterology. 1994; 106: 1284-1290
- Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.J Hepatol. 2003; 39: 12-16
- Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis.Gastroenterology. 1996; 110: 1515-1518
- Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients.Clin Transpl. 2006; 20: 211-220
- Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.Liver Transpl. 2007; 13: 1236-1245
Article info
Publication history
Published online: December 28, 2020
Accepted:
December 4,
2020
Received:
August 3,
2020
Identification
Copyright
© 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
